PASG:NASDAQPassage Bio, Inc. Analysis

Passage Bio is trading well beneath its short‑term moving averages, with the current price under the 20‑day and 50‑day SMAs and a bearish MACD histogram. Momentum indicators such as an RSI hovering just below the 40‑point threshold and a declining volume trend underscore short‑term weakness, while a 30‑day volatility exceeding 100% and a computed beta above 2 signal extreme price swings.
Fundamentally, the company has no revenue and reports negative EBITDA and cash flow, yet it holds a net cash position that exceeds its modest debt, and its price‑to‑book ratio sits just above one, suggesting a valuation that could be considered cheap on a balance‑sheet basis. Recent headlines about the firm reviewing strategic alternatives hint at a possible catalyst, but the lack of commercial products and the high regulatory hurdles inherent to CNS gene‑therapy programs keep the risk profile elevated.